Streetbeat News

Analyst Ratings

VRTX

HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating on Vertex Pharmaceuticals (NASDAQ:VRTX) and maintained a price target of $462.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:45 am

ZETA

Oppenheimer analyst Brian Schwartz maintains an Outperform rating on Zeta Global Holdings (ZETA) and raises the price target from $14 to $18.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:45 am

WES

Mizuho analyst Gabriel Moreen maintains a Buy rating on Western Midstream (NYSE:WES) and raises the price target from $34 to $39.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:43 am

LCID

Needham analyst Chris Pierce reiterates a Hold rating on Lucid Group (LCID), indicating no change in the investment firm's stance towards the electric vehicle manufacturer's stock.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:42 am

MCHP

Mizuho analyst Vijay Rakesh has maintained a Neutral rating on Microchip Technology (NASDAQ:MCHP) and increased the price target from $82 to $85.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:42 am

TGT

Target's stock price increased following an upgrade from Neutral to Buy by Citigroup.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:41 am

IFF

Mizuho analyst John Roberts has maintained a Neutral rating on Intl Flavors & Fragrances (IFF) and increased the price target from $91 to $98.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:40 am

GPRE

B of A Securities analyst Steve Byrne has maintained a Buy rating on Green Plains (NASDAQ:GPRE) but lowered the price target from $29 to $26.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:37 am

BTCUSD

ETHUSD

Prominent crypto analyst Capo Of Crypto predicts Ethereum (ETH) will outperform Bitcoin (BTC) in the coming days, citing a strong bounce from the support zone and potential bullish continuation for ETH. The analysis also highlights the strength of the ETH/BTC pair and anticipates Ethereum ETFs' approval as a significant upcoming event that could further boost ETH's performance. However, skepticism exists regarding the timeline for Ethereum ETF approval, with some analysts suggesting a delay until 2025.

Portfolio Pulse from Khyathi Dalal

May 07, 2024 | 11:37 am

IART

B of A Securities analyst Craig Bijou maintains an Underperform rating on Integra Lifesciences (NASDAQ:IART) and lowers the price target from $42 to $26.

Portfolio Pulse from Benzinga Newsdesk

May 07, 2024 | 11:35 am